Check-Cap Future Growth

NasdaqCM:CHEK - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	N/A	-4	N/A	N/A	1
12/31/2023	N/A	-13	N/A	N/A	1
9/30/2023	N/A	-18	-18	-18	N/A
6/30/2023	N/A	-20	-18	-18	N/A
3/31/2023	N/A	-18	-19	-18	N/A
12/31/2022	N/A	-19	-19	-19	N/A
9/30/2022	N/A	-21	-20	-19	N/A
6/30/2022	N/A	-20	-20	-19	N/A
3/31/2022	N/A	-19	-19	-18	N/A
12/31/2021	N/A	-17	-17	-16	N/A
9/30/2021	N/A	-16	-16	-15	N/A
6/30/2021	N/A	-15	-15	-15	N/A
3/31/2021	N/A	-14	-13	-13	N/A
12/31/2020	N/A	-14	-13	-13	N/A
9/30/2020	N/A	-14	-13	-13	N/A
6/30/2020	N/A	-14	-13	-13	N/A
3/31/2020	N/A	-14	-13	-13	N/A
12/31/2019	N/A	-14	-13	-13	N/A
9/30/2019	N/A	-13	-12	-12	N/A
6/30/2019	N/A	-12	-12	-12	N/A
3/31/2019	N/A	-12	-12	-11	N/A
12/31/2018	N/A	-11	-10	-10	N/A
9/30/2018	N/A	-9	-9	-9	N/A
6/30/2018	N/A	-9	-9	-9	N/A
3/31/2018	N/A	-9	-9	-9	N/A
12/31/2017	N/A	-10	-9	-9	N/A
9/30/2017	N/A	-10	-9	-9	N/A
6/30/2017	N/A	-10	N/A	-8	N/A
3/31/2017	N/A	-9	N/A	-8	N/A
12/31/2016	N/A	-9	N/A	-8	N/A
9/30/2016	N/A	-10	N/A	-8	N/A
6/30/2016	N/A	-11	N/A	-10	N/A
3/31/2016	N/A	-12	N/A	-8	N/A
12/31/2015	N/A	-13	N/A	-9	N/A
9/30/2015	N/A	-10	N/A	N/A	N/A
6/30/2015	N/A	-7	N/A	-6	N/A
3/31/2015	N/A	-7	N/A	N/A	N/A
12/31/2014	N/A	-3	N/A	-4	N/A
9/30/2014	N/A	-3	N/A	N/A	N/A
6/30/2014	N/A	-4	N/A	-4	N/A
3/31/2014	N/A	-4	N/A	N/A	N/A

Analyst Future Growth Forecasts

Einkommen vs. Sparrate: CHEK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CHEK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CHEK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von CHEK schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: CHEK wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Earnings per Share Growth Forecasts

Future Return on Equity

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CHEK in 3 Jahren voraussichtlich hoch sein wird

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Check-Cap Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$3.00

No longer forecast to breakeven

Recent updates

New minor risk - Share price stability

Nobul AI Corp entered into a definitive Business Combination Agreement to acquire Check-Cap Ltd. (NasdaqCM:CHEK).

Check-Cap Ltd. Announces Executive Changes

Check-Cap Ltd. Announces CFO Changes

Check-Cap Ltd. Announces Resignation of William Vozzolo as Member of the Board of Directors and Independent Member of the Audit Committee

Check-Cap Ltd. Announces Resignation of William Vozzolo as Member of the Board of Directors and Independent Member of the Audit Committee

Symetryx Corporation Recommends Shareholders to Vote Against the Keystone Dental Merger and For its Board Nominees

Symetryx Corporation Discloses its Views on Check-Cap

New major risk - Revenue and earnings growth

SBT Holdings Inc. entered into a definitive Business Combination Agreement to acquire Check-Cap Ltd. (NasdaqCM:CHEK) in a reverse merger transaction.

Check-Cap Ltd. Reports Impairment of Fixed Assets for the Second Quarter Ended June 30, 2023

We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate

Here's Why We're Watching Check-Cap's (NASDAQ:CHEK) Cash Burn Situation

Insufficient new directors

Check-Cap Ltd., Annual General Meeting, Dec 22, 2022

We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate

Check-Cap Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Here's Why We're Not Too Worried About Check-Cap's (NASDAQ:CHEK) Cash Burn Situation

Check-Cap Ltd. Announces the Initiation of its U.S. Pivotal Trial of C-Scana at Mayo Clinic in Rochester Minnesota

Price target decreased to US$3.00

Insufficient new directors

Check-Cap Ltd. Receives Approval from the U.S. Food and Drug Administration for Its Amended Investigational Device Exemption Application

We Think Check-Cap (NASDAQ:CHEK) Can Afford To Drive Business Growth

Check-Cap Announces Receipt of Nasdaq Minimum Bid Price Notification

Check-Cap Ltd. Announces Publication of Peer-Reviewed Article Highlighting Safety and Patient Satisfaction Data for Its Colorectal Screening Test, C-Scan

We're Hopeful That Check-Cap (NASDAQ:CHEK) Will Use Its Cash Wisely

Check-Cap (NASDAQ:CHEK) Is In A Good Position To Deliver On Growth Plans

No longer forecast to breakeven

Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan®

New 90-day high: US$2.33

New 90-day high: US$1.85

We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate

New 90-day high: US$0.43

Check Cap +1.5% on listing extension from NASDAQ

New 90-day high: US$0.41

Check-Cap EPS misses by $0.01

New 90-day low: US$0.31

New 90-day low: US$0.34

New 90-day low - US$0.39

New 90-day high - US$0.80

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies